Subject: A multi-centric, cross-sectional and observational survey study to understand the role of Olopatadine eye drops for the treatment of ocular itching associated with allergic conjunctivitis.
Conjunctivitis is a broad word used to describe a variety of conditions that predominantly affect the conjunctiva and is often associated with the inflammation of the conjunctiva.1 Conjunctivitis usually resolves on its own, but some types progress and may result in serious ocular and extraocular problems.1 Acute, chronic, or recurring conjunctivitis can be categorised as either infectious or noninfectious as well. One of the most prevalent allergic condition worldwide and a type of conjunctivitis is allergic conjunctivitis.2
Early detection and treatment can save a person's sight and, in rare circumstances, their life.1 Treatment options for mild allergic conjunctivitis include second-generation topical histamine H1-receptor antagonists, which are more effective than over-the-counter topical antihistamine/vasoconstrictor medications.1 Topical antibiotics and corticosteroids shouldn't be used carelessly.1
Olopatadine 0.1% approved for the treatment of the signs and symptoms of allergic conjunctivitis, was the first dual-action topical medication to alter the therapeutic paradigm. Subsequently, olopatadine 0.2% was introduced with improved satisfaction and comparable efficacy, olopatadine 0.7% is the latest generation of this molecule, for once-daily dosing. Olopatadine has showed superiority over the second-generation topical and oral antihistamines (fexofenadine, levocabastine, and loratadine), the mast-cell stabilizers (cromolyn sodium and nedocromil sodium), the NSAID ketorolac, and the corticosteroids (fluorometholone and loteprednol in numerous comparative studies. Additionally, olopatadine was found to be more comfortable than levocabastine, ketorolac, and nedocromil sodium.2
Olopatadine eye drops is marketed by the Avesta team of Sun Pharma as ‘Winolap DS’ and ‘Winolap max’
This multicentric cross-sectional survey study is planned to understand the role of Olopatadine eye drops in the treatment of ocular itching associated with allergic conjunctivitis.
We invite you to participate in this study and share your experience through a cross-sectional survey, thus, it is not an experimental/interventional study.
We trust you and we are partners in promoting safe effective medical therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}